Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.34 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30301878 | 1.00 | TAAR1 (0.42) | TAAR1KAT2BIDO1TSHRCYP1A2 | |
| SCHEMBL28312340 | 0.84 | KAT2B (0.47) | KAT2BMCL1MYC | |
| SCHEMBL20096042 | 0.81 | KAT2B (0.35) | KAT2B | |
| SCHEMBL28956417 | 0.79 | TAAR1 (0.47) | TAAR1IDO1TSHRCYP1A2CYP2D6 | |
| SCHEMBL13568961 | 0.77 | MEN1 (0.35) | KAT2BIDO1TSHRLMNAMYC | |
| SCHEMBL31167361 | 0.77 | KAT2B (0.33) | KAT2B | |
| SCHEMBL31167358 | 0.76 | PYCR1 (0.37) | KAT2BPYCR1MCL1 | |
| SCHEMBL17399958 | 0.75 | KAT2B (0.41) | KAT2BTSHRMCL1 | |
| SCHEMBL19743373 | 0.75 | KAT2B (0.41) | KAT2BTSHRMCL1 | |
| SCHEMBL21594374 | 0.75 | HSPA5 (0.48) | TAAR1KAT2BIDO1TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234220-B2 | Immunomodulatory compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4358948-A1 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230053649-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2022272036-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20210284624-A1 | IMMUNOMODULATORY COMPOUNDS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| EP-3814330-A1 | IMMUNOMODULATORY COMPOUNDS | Dana-Farber Cancer Institute, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284624-A1 | IMMUNOMODULATORY COMPOUNDS | CRBN, CD47, CD58 | TAAR1 4451/4885KAT2B 3643/4885IDO1 219/4885 |
| US-12234220-B2 | Immunomodulatory compounds | CRBN, CD47, CD58 | TAAR1 4451/4885KAT2B 3643/4885IDO1 219/4885 |
| US-20230053649-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TAAR1 4592/4885KAT2B 2191/4885IDO1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.